Drugs / BMS-582949
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00162292 | Nov 2005 → Oct 2007 | rheumatoid arthritis | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT00570752 | Dec 2008 → Nov 2010 | vascular disorder | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 2 | NCT00605735 | Mar 2008 → Aug 2009 | rheumatoid arthritis | Bristol-Myers Squibb | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00399906 Comparator | Aug 2007 → Jan 2009 | psoriasis | Bristol-Myers Squibb | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BMS-582949 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00162292 ↗ |
| Known as | PS-540446 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1230065 ↗ |
| Action | Inhibit | “MAP kinase p38 alpha inhibitor” CHEMBL1230065 ↗1“p38MAPK inhibitor” PMID 25913664 ↗ Mar 2015 |
| Modality | Small molecule | — CHEMBL1230065 ↗ |
| Route | Oral | “Tablets, Oral, Once daily, 12 weeks” NCT00399906 ↗ |
| Target | MAPK14 | “MAP kinase p38 alpha inhibitor” CHEMBL1230065 ↗ |